(redirected from Bepreve)


(be-poe-tass-teen) ,


(trade name)


Therapeutic: ocular agents
Pharmacologic: antihistamines
Pregnancy Category: C


Treatment of itching associated with allergic conjunctivitis.


Acts as a histamine H1 receptor antagonist; also inhibits the release of histamine from mast cells; does not bind to or inactivate histamine.

Therapeutic effects

Decreased ocular itching associated with allergic conjunctivitis.


Absorption: Some systemic absorption follows ophthalmic administration.
Distribution: Unknown.
Metabolism and Excretion: Minimally metabolized by the liver; 75–90% excreted unchanged in urine.
Half-life: Uknown.

Time/action profile (antihistaminic activity)

ophthwithin 15 min1–2 hr†12 hr
†blood levels


Contraindicated in: Hypersensitivity.
Use Cautiously in: Contact lens use ; Obstetric: Use during pregnancy potential maternal benefit justifies the potential risk to fetus; Lactation: Use cautiously during breastfeeding; Pediatric: Safe and effective use in children <2 yr has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • headache

Ear, Eye, Nose, Throat

  • nasopharyngitis


  • taste in mouth following instillation (most frequent)


Drug-Drug interaction

None noted.


Ophthalmic (Adults) One drop in affected eye(s) twice daily.


Ophthalmic solution: 1.5%

Nursing implications

Nursing assessment

  • Assess signs and symptoms of allergic conjunctivitis (redness, itching, watering) periodically during therapy.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Ophthalmic: Instill 1 drop into affected eyes twice daily. See for administration guidelines.

Patient/Family Teaching

  • Instruct patient to instill bepotastine drops as directed. Do not touch dropper to eye or to any surface.
  • Advise patient to remove contact lens prior to instillation. Do not use bepotastine for treatment of irritation related to contact lens. Do not wear contact lens if eyes are red. Contact lens may be reinserted 10 min following instillation.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Decrease in ocular itching due to allergic conjunctivitis.
References in periodicals archive ?
Bepreve reduced eye itching "with few mild and transient" side effects, the company said in a separate summary released by FDA staff.
The other drug classes are comprised of ISTA pharmaceuticas Bepreve, Allergans Elestat, and Alcons Emadine and Alomide.
ISTA's four prescription products, BROMDAY(TM), BEPREVE, ISTALOL, and VITRASE, will complement Bausch + Lomb's existing prescription ophthalmology products, including Lotemax and Besivance, and branded OTC eye vitamins PreserVision and Ocuvite.
Net revenue growth was driven primarily by strong demand for XIBROM(TM) and BEPREVE, supported by revenue increases in VITRASE.
Product gross margin improved due to increased sales of our higher gross margin products, XIBROM and BEPREVE.
based ophthalmologists, along with BEPREVE, our recently launched eye drop for the treatment of itching associated with allergic conjunctivitis.
The Phase 1/2 study data with bepotastine besilate nasal sprays supports our initial findings with the BEPREVE ophthalmic solution on the efficacy of bepotastine for the treatment of nasal symptoms.
BEPREVE, for ocular itching associated with allergic conjunctivitis, had a strong adoption rate during its first spring allergy season among U.
Last year, we received FDA approval for BEPREVE, our eye drop treatment for itching associated with allergic conjunctivitis.
Our goals are to build Bepreve into a leading ocular allergy treatment and maximize Xibrom's leadership position in the cataract surgery market.